SARS-CoV-2 RdRp-IN-1

SARS-CoV-2 RdRp-IN-1 (Compound PAP-2) is a potent SARS-CoV-2 RdRp inhibitor, with an EC50 of 1.11 μM. SARS-CoV-2 RdRp-IN-1 can bind directly to SARS-CoV-2 RdRp, fully resistance to the exoribonuclease (ExoN) and exhibit broad spectrum anti-CoV activities[1].

Product Specifications

UNSPSC

12352005

Target

SARS-CoV

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Smiles

NC1=CC=C(/N=N/C2=CC=CC=C2)C(NC(C3CCCN3C(OC(C)(C)C)=O)=O)=N1

Molecular Formula

C21H26N6O3

Molecular Weight

410.47

References & Citations

[1]Zhao J, et, al. Discovery and optimization of phenazopyridine hydrochloride as novel SARS-CoV-2 RdRp inhibitors. Eur J Med Chem. 2025 Apr 15:288:117422.